Follistatin 315 Research Peptide: Protein Identity, Isoforms, and COA Verification

Introduction

Follistatin 315 research peptide is a misleading market label when it implies a small, undefined synthetic fragment. Native FST315 is a full 315-amino-acid secreted glycoprotein isoform with an N-terminal domain, three follistatin domains, conserved disulfide architecture, and post-translational features. Comparative isoform studies treat FST315 as a folded ligand-binding protein whose behavior depends on domain structure and cell-surface association, not as a generic peptide defined by a product name.

That distinction sets the analytical burden. A vial labeled "Follistatin 315" cannot be assumed to contain authentic, full-length, correctly folded, glycosylated FST315. Sequence coverage, intact mass, purity, higher-order structure, aggregate state, and ligand-neutralizing bioactivity must support the claim. This article concerns laboratory characterization and research interpretation only. It does not address administration, treatment, or human use.

What is Follistatin 315?

FST315 is one mature product of the human FST gene. A signal peptide directs the nascent chain through the secretory pathway and is removed, leaving the 315-residue extracellular protein. Work on follistatin biosynthesis and intracellular transport found that FST315 is secreted faster than FST288 under the studied cell conditions. The mature protein is commonly described as the more soluble circulating isoform because its acidic C-terminal extension limits the heparan-sulfate binding seen with shorter forms.

Calling FST315 a peptide is chemically loose. Proteins and peptides are both amino-acid polymers, but a 315-residue, cysteine-rich, secreted glycoprotein has analytical requirements that a short linear synthetic peptide does not. Disulfide pairing, domain folding, glycan occupancy, proteolytic clipping, and self-association can change function without changing the nominal amino-acid list printed on a label.

FST315 vs FST288 vs FST344

• FST315 is the mature 315-residue secreted isoform with an acidic 27-residue C-terminal region relative to FST288. Its lower affinity for cell-surface heparan sulfate favors a more soluble distribution.
• FST288 is a mature 288-residue isoform produced from an alternatively spliced transcript. Its exposed basic heparan-sulfate-binding region promotes association with cell surfaces and extracellular matrices.
• FST303 is an intermediate form generally attributed to proteolytic processing of the FST315 C-terminus. Its surface-binding behavior falls between FST288 and FST315.
• FST344 usually names the 344-amino-acid precursor or the cDNA construct that encodes it. Removal of the signal peptide produces mature FST315. Treating FST344 and FST315 as interchangeable vial contents confuses a precursor/transgene designation with the processed secreted product.

The numbering therefore answers different questions. FST344 describes what is translated before secretion-associated processing. FST315 describes one mature chain. FST288 describes a shorter mature chain created through alternative splicing, while FST303 reflects C-terminal proteolysis. A supplier should state which sequence begins and ends in the vial, rather than relying on a familiar number with no sequence record.

How does follistatin bind myostatin and activin?

Follistatin is an extracellular ligand trap. It wraps around dimeric TGF-beta-family ligands and blocks receptor-contact surfaces before those ligands can assemble signaling receptor complexes. Domain-mapping experiments show that the N-terminal region and individual follistatin domains make different contributions to activin A and myostatin antagonism. A positive binding assay against one ligand therefore does not establish native behavior across the full ligand panel.

For myostatin, sequestration prevents productive engagement of activin type II receptors and the downstream receptor system that drives SMAD2/3 signaling. Early myostatin regulation experiments showed that follistatin can inhibit myostatin activity, but also showed that the biology cannot be reduced to one ligand. Follistatin-related effects exceeded what myostatin blockade alone predicted in animal models, pointing to sequestration of other TGF-beta-family members.

Follistatin is not a selective myostatin switch

Activins are high-affinity follistatin ligands, and studies have also examined interactions with selected bone morphogenetic proteins. Binding preferences differ among FST315, FST303, FST288, and follistatin-like 3. Surface localization changes apparent antagonism because a protein retained near receptors can intercept locally produced ligand differently from a soluble protein in bulk medium. An assay result must name the isoform, ligand, cell context, concentration range, and endpoint.

This nonselectivity matters when interpreting a COA. A generic statement such as "myostatin inhibitor" does not identify the molecule, quantify affinity, prove neutralization, or exclude broad activin binding. The phrase compresses several distinct measurements into a marketing claim. For laboratory planning, those measurements must remain separate.

Why a commercial label cannot establish FST315 identity

A product name is metadata, not molecular evidence. The distinction becomes sharper for a secreted glycoprotein because expression host, purification strategy, protease exposure, oxidation conditions, and storage can alter the final material. Our guide to manufacturing source and verification explains why traceability and orthogonal testing belong beside purity. For FST315, the source should also disclose whether the material was recombinantly expressed, isolated from a biological matrix, or assembled by another method.

A short synthetic fragment can produce a clean chromatographic peak while having no claim to full-length FST315 identity. A full-length chain with the expected average mass can still be misfolded. A correctly folded monomer can carry a different glycan distribution from native or reference recombinant material. A pure monomer can still fail to neutralize activin or myostatin. Each analytical layer answers one question and leaves the others open.

Six evidence layers that must stay separate

• Protein identity: peptide mapping should cover the expected FST315 sequence, including the isoform-defining C-terminus. N-terminal and C-terminal confirmation can detect precursor retention or clipping.
• Intact mass: deconvoluted mass data should be interpreted against the expressed construct, signal-peptide processing, disulfide state, and glycoforms. A peptide mass fingerprint alone is not intact-protein confirmation.
• Purity: reversed-phase or ion-exchange chromatography can quantify resolved species under stated conditions, but one area-percent number does not identify every impurity or prove native structure.
• Folding and disulfides: nonreducing electrophoresis, disulfide mapping, circular dichroism, or a suitable conformational method should address higher-order structure rather than infer it from sequence.
• Glycosylation: glycan occupancy and distribution should be reported when the claimed material is glycosylated. A broad mass envelope is not a substitute for a documented glycan analysis.
• Aggregate state and bioactivity: size-exclusion chromatography should quantify monomer and higher-molecular-weight species. A ligand-binding assay and a cell-based neutralization assay should then test binding and functional antagonism as separate properties.

What must a Follistatin 315 COA prove?

A defensible certificate should connect every result to one lot, one stated construct, and one test method. Start in the COA library by matching the lot number on the vial to the certificate, then check whether the document proves the following points rather than repeating the product name. Method suitability matters as much as method names. Reported limits of detection, system-suitability results, reference-standard provenance, and raw-data identifiers make the certificate auditable. Without them, a passing result may be impossible to reproduce or compare across lots.

1. The exact mature sequence, residue numbering convention, termini, expression host, signal-peptide processing, and any affinity-tag history.
2. Sequence identity through LC-MS/MS peptide mapping with reported coverage and direct evidence for the FST315-specific C-terminal region.
3. Intact-protein mass under defined conditions, with an explanation of glycoform heterogeneity and agreement limits rather than a bare theoretical value.
4. Purity, disulfide integrity, glycosylation, monomer percentage, aggregates, fragments, and host-cell contaminants measured by suitable orthogonal methods.
5. Binding kinetics or affinity for a named ligand, plus cell-based inhibition of a named activin or myostatin pathway against a qualified reference standard.
6. Lot release context, including test dates, laboratory identity, method references, acceptance criteria, endotoxin when relevant to the planned research system, and storage stability.

COA red flags

Warning signs include a molecular weight compatible with a short fragment, no disclosed sequence, "HPLC purity" as the sole identity test, chromatograms without sample or lot metadata, a single mass-to-charge peak presented as proof of a glycoprotein, and bioactivity described without ligand, reference standard, curve, or potency calculation. Another warning is a certificate that switches among FST315, FST344, and "follistatin peptide" as if those names identify the same molecular material.

Interpreting fragment research without relabeling it FST315

A follistatin-derived fragment can be a legitimate research object when its sequence and limits are explicit. For example, work on a follistatin-derived inhibitory peptide investigated a defined derivative in a mouse model. Such evidence belongs to that derivative, not automatically to native FST315 or to an unlabeled commercial fragment. Researchers comparing reagents in tissue-repair research should preserve this identity boundary when selecting controls and interpreting pathway effects.

The same discipline applies across assay systems. Recombinant FST288 data do not establish FST315 localization. A gene-delivery construct labeled FS344 does not prove that a vial contains precursor FST344. An activin-binding ELISA does not prove myostatin neutralization in cells. Clear nouns prevent borrowed evidence: precursor, mature isoform, proteolytic product, fragment, and commercial material should remain distinct throughout the protocol and report.

FST315 is a protein, not a peptide. Calling it one doesn't lower the analytical bar it has to clear.

Conclusion

Native FST315 is a 315-amino-acid secreted glycoprotein isoform, not an undefined short synthetic peptide. FST288 and FST315 arise from alternative transcripts and differ at the C-terminus, which changes heparan-sulfate binding and localization. FST344 usually identifies the precursor or encoding construct that is processed to mature FST315. Proteolysis can produce intermediate FST303.

Follistatin sequesters activin, myostatin, and selected related ligands, so "myostatin inhibitor" is an incomplete identity and function claim. Before using material labeled Follistatin 315, require lot-linked evidence for sequence, intact mass, purity, disulfide-dependent folding, glycosylation, aggregate state, and bioactivity. If those data are absent, the defensible description is "material sold as Follistatin 315," not authentic full-length FST315. Research use only.

When lot-linked FST315 records are listed for qualified laboratories, Tetrava Labs publishes batch-specific COA documentation alongside related tissue-repair research compounds. Research use only.

Frequently Asked Questions (FAQ)

What is Follistatin 315? The full 315-amino-acid mature secreted glycoprotein isoform encoded by the human FST gene, not an undefined short synthetic peptide fragment.

What is the difference between FST315 and FST288? Alternative splicing produces two mature chains that differ at the C-terminus. FST288 carries an exposed heparan-sulfate-binding region and stays near cell surfaces; FST315 is more soluble and circulates more freely.

Is FST344 the same as FST315? No. FST344 usually names the signal-peptide-containing precursor or the encoding construct. Removal of that signal peptide produces mature FST315.

What must a Follistatin 315 COA prove? Sequence identity through peptide mapping, intact-protein mass, disulfide-dependent folding, glycosylation, and ligand-binding or neutralization bioactivity, reported as separate, named tests rather than one purity number.